{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ganz PA"],"funding":["NCI NIH HHS"],"pagination":["3942-3948"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5721228"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(35)"],"pubmed_abstract":["Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive and disease free, which included measurement of left ventricular ejection fraction by multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status Index "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2."],"pmcid":["PMC5721228"],"funding_grant_id":["UG1 CA189867","U10 CA180868","U10 CA180822"],"pubmed_authors":["Jeong JH","Wade JL","Polikoff J","Flynn PJ","Brufsky AM","Seay TE","Biggs DD","Fehrenbacher L","Gross HM","Ganz PA","Wahl TA","Cecchini RS","Romond EH","Zapas JL","Mamounas EP","Rastogi P","Geyer CE","Atkins JN","Wolmark N","Swain SM"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.","description":"Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive and disease free, which included measurement of left ventricular ejection fraction by multigated acquisition scan along with patient-reported outcomes using the Duke Activity Status Index ","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2025-04-19T12:33:03.83Z","creation":"2019-03-27T00:10:55Z"},"accession":"S-EPMC5721228","cross_references":{"pubmed":["29072977"],"doi":["10.1200/JCO.2017.74.1165","10.1200/jco.2017.74.1165"]}}